PP-52 - Poor Dual Antiplatelet Therapy Adherence May Not Be the Primary Predictor of Bioresorbable Vascular Scaffold Thrombosis

Abstract

Introduction: The duration of dual antiplatelet therapy (DAPT) is one of the major concerns in interventional cardiology. The optimal DAPT duration after bioresorbable vascular scaffold (BVS) implantation is not clear. The general consensus favours a longer DAPT duration after scaffolding. Several case reports have shown that discontinuation of DAPT after a year may lead to late scaffold thrombosis, suggesting the need to extend DAPT beyond a year. Moreover, clinical usage of Absorb BVS was restricted by the manufacturer company due to high rate of late thrombosis. Herein, we propose that poor DAPT adherence may not be the primary predictor of BVS thrombosis in the light of a new case report.